I can see I shall have to "lose" hypo awareness pretty quickly now.
The response from North Hants is
Diabetes
Current Statement in regards to Flash Glucose Monitoring (FreeStyle Libre)
The CCG agreed on Friday 23 February 2018 to adopt recommendations made by the local Southampton, Hampshire, Isle of Wight, Portsmouth (SHIP8) Priorities Committee about the commissioning of ‘flash’ glucose monitoring systems, such as FreeStyle Libre.
Whilst the CCG has agreed the SHIP8 Priorities Committee recommendations, there are now some important details to work through and agree with our service providers about how these will be adopted in practice. The Priorities Committee has scheduled for further review in early 2019.
The SHIP8 Priorities Committee guidance has been considered alongside other national guidance as well as the NHS England Regional Medicines Optimisation Committee advisory statement on Flash Glucose Monitoring systems.
You can view the policy recommendation document Below
(Draft Policy Recommendation: ‘Flash’ Glucose Monitoring in Diabetes
Date of Issue: Jan 2018
The prescribing of ‘flash’ glucose monitors in diabetes in patients 4 years and above
‘Flash’ glucose monitoring systems such as the Freestyle Libre may be recommended in patients
with Type 1 diabetes or those with Type 1 or 2 diabetes who are pregnant and who fulfil one or more
of the criteria below:
· Patients who are required to undertake intensive monitoring with 8 or more finger prick blood
tests daily. This does not apply to those who chose to frequently finger prick test.
· Those who meet the current NICE criteria for insulin pump therapy (HbA1c >69.4mmol/mol)
or disabling hypoglycaemia as described in NICE TA151 where a successful trial of flash
glucose monitoring may avoid the need for pump therapy
· Those who have recently developed impaired awareness of hypoglycaemia, when it may be
used as an initial tool in its management with a review at 6 months.
· Frequent (>2 per year) hospital admissions with diabetic ketoacidosis or hypoglycaemia
where other management plans have failed.
· Those requiring third parties to carry out monitoring or where conventional blood testing is not
possible.
This method of monitoring must not be initiated in a primary care setting and should only be initiated,
or recommended, by the consultant-led service and who fulfil the criteria below:
· The patient should have previously been through an advanced insulin self-management
education course such as “DAFNE” (Dose adjustment for normal eating: DH, 2002)1 or local
accredited education programmes. The patient should be actively engaged in enrolling
themselves into the management system and would be expected to go through a further
course of education on the use and interpretation of the readings the management system
delivers.
o Primary care may be subsequently asked to prescribe the monitoring sensor packs in
the community for people who fulfil the above criteria. This should lead to a reduction
in use of prescribed Blood Glucose Testing Strips (see below)
· If no improvement is demonstrated in one or more of the impact areas below over a 6 month
trial period, then the use of Flash glucose monitoring should be reviewed with alternative
method of monitoring considered.
· Reductions in severe/non-severe hypoglycaemia
· Reversal of impaired awareness of hypoglycaemia
· Episodes of diabetic ketoacidosis
· Admissions to hospital
· Reduction in HbA1c by more than 0.5% where appropriate
· Blood Glucose Testing strip usage reduced
· Quality of Life changes using validated rating scales
· Commitment to regular scans and their use in self-management.
The use of Flash Glucose Monitoring systems for any other indication is outside of the pathway are
considered low priority and will be subject to an IFR process.)
Additional useful information
Please be aware that FreeStyle Libre is not currently endorsed by the DVLA as a sole method of monitoring and in order to meet the national regulations patients who drive must still test using a standard blood glucose meter.
Patients fulfilling the criteria for prescribing are likely to be seen by a specialist at their routine appointment.
Patients who have obtained FGS through clinical trials or private treatment, or who have been self-funding, must demonstrate that they satisfied the prescribing criteria when they commenced the use of FGS as well as meeting the continuation criteria, to receive FGS on NHS prescription.
So there we go.